| Followers | 24 |
| Posts | 1425 |
| Boards Moderated | 0 |
| Alias Born | 01/27/2021 |
Thursday, May 11, 2023 10:29:10 AM
That's about the best slideshow presentation I've ever seen related to Vascepa. Can Amarin borrow some of these concepts for their own promotional materials?
And this is the first time I've seen it spelled out how teaming up with Pfizer to reach general practitioners is paying off in a big way. KM had suggested that Pfizer might be able to do that in other markets. Like the U.S.???
It's been two years since Pfizer started doing this in Canada and yet Amarin hasn't convinced them to do this elsewhere?
Denner's team is misunderstanding what we mean when we want more communication with shareholders. We don't need to hear that Denner's folks were caught by surprise when KM and the entire board resigned. Not expecting that or planning for it sounds like incompetence on Denner's part and makes some people want to sell their shares. Thus, the daily share price plunge.
What we want to hear in communications is that the company is doing something, anything, to try to show it has new life and is enthusiastically embracing the future with new ideas. Maybe a deal with Pfizer to reach general practitioners in the U.S. and Europe?
And this is the first time I've seen it spelled out how teaming up with Pfizer to reach general practitioners is paying off in a big way. KM had suggested that Pfizer might be able to do that in other markets. Like the U.S.???
It's been two years since Pfizer started doing this in Canada and yet Amarin hasn't convinced them to do this elsewhere?
Denner's team is misunderstanding what we mean when we want more communication with shareholders. We don't need to hear that Denner's folks were caught by surprise when KM and the entire board resigned. Not expecting that or planning for it sounds like incompetence on Denner's part and makes some people want to sell their shares. Thus, the daily share price plunge.
What we want to hear in communications is that the company is doing something, anything, to try to show it has new life and is enthusiastically embracing the future with new ideas. Maybe a deal with Pfizer to reach general practitioners in the U.S. and Europe?
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
